The pharma giant will pay $1.2 billion up-front for efimosfermin, with the deal including potential success-based milestone ...

GSK will buy efimosfermin, a specialty medicine used to treat liver disease from Boston Pharmaceuticals, for up to $2 billion ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

From Burberry’s planned job cuts and Aviva’s £3.7bn takeover probe to China’s criticism of the UK-US trade pact, here are ...

GSK Pharma reported a 35% rise in net profit to Rs 263 crore in Q4 FY25, while Aditya Birla Capital reported a net profit of ...

Affecting up to 5% of the global population, SLD represents an area of significant unmet medical need with limited treatment optionsPhase II data show ...

GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

GSK Pharma reports 35 per cent YoY rise in Q4FY25 profit led by gains in general medicines and vaccines; oncology launches ...

GSK said it remains confident in its ability to absorb the financial impact of potential US pharmaceutical tariffs as it ...

(Reuters) -iTeos Therapeutics and partner GSK said on Tuesday they have terminated development of their experimental lung ...